X4 Pharmaceuticals Inc
NASDAQ:XFOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X4 Pharmaceuticals Inc
NASDAQ:XFOR
|
US |
Intrinsic Value
The intrinsic value of X4 Pharmaceuticals Inc (XFOR) under the Base Case is 2.68 USD per share.
Compared with the current market price of 3.07 USD, the stock appears
Overvalued by 13% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What X4 Pharmaceuticals Does
X4 Pharmaceuticals is a drug developer focused on rare immune disorders. Its main product is mavorixafor, an oral medicine sold in the U.S. as Xolremdi for WHIM syndrome, a genetic condition that leaves patients with too few white blood cells and frequent infections. The company’s work is centered on finding and bringing to market medicines that help patients whose immune systems do not work properly.
- Headquarters
- United States of America US
- Employees
- 45
- IPO date
- Nov 16, 2017
X4 Pharmaceuticals has no economic moat
Doctors can choose XOLREMDI or other ways to manage WHIM-related problems, and each prescription benefits only the patient receiving it. Nothing about using the drug makes it more valuable to other patients or prevents other treatments from competing for their care.
Read the full moat analysis
Revenue & Expenses Breakdown
X4 Pharmaceuticals Inc
Earnings Waterfall
X4 Pharmaceuticals Inc
The intrinsic value for X4 Pharmaceuticals Inc (XFOR) under the Base Case is 2.68 USD.
Compared with the current market price of 3.07 USD, the stock appears Overvalued by 13% .
